Pacific Biosciences of California reported third-quarter revenue of $40.6 million, exceeding the $39.3 million consensus estimate from FactSet, MarketScreener reported on November 4. The beat, or roughly 3.3 percent, sent shares up 4.51 percent to $2.55. The market closed at 22:00 on November 4, 2026, and the report was published at 23:14 that day.
The sequencing company, which specializes in HiFi long-read technology, has seen its stock rise 4.08 percent since January 1 and 36.36 percent over the past year, according to the report.
AI Partnerships Expand Biomedical Genomics Reach
On October 19, the company and Verily Health announced a multi-year collaboration to scale long-read genomics for biomedical AI, MarketScreener reported. Earlier that month, on October 6, PacBio partnered with TychoBio to generate full-length RNA data for training AI models targeting rare-disease therapeutics.
Restructuring Plan Targets $40 Million in Annual Savings
The company announced a restructuring plan on August 5 that will cut 8 percent of its workforce, with annual savings of up to $40 million expected by 2027, according to MarketScreener. The plan was announced alongside second-quarter and first-half results for the period ended June 30, 2026. The same day, Pacific Biosciences disclosed a chief executive change effective August 5 and issued revenue guidance for the full year 2026.
Insider Sale Follows Leadership Transition
On October 8, an insider sold shares worth $2,056,921, as disclosed in a Securities and Exchange Commission filing cited by MarketScreener.
$PACB now 50% up since ✅ https://t.co/p14G2UG7Rv pic.twitter.com/Ot8zi0pazt
New Chemistry and Software Update Released in August
On July 9, Pacific Biosciences announced the availability of SPRQ-Nx chemistry and a software update for the Vega sequencing system.
Board Member Resigns
On July 9, the company disclosed that board member Christopher M. Smith would resign effective July 8, 2026.
Morgan Stanley Conference Presentation
On September 15 at 4:50 p.m., Pacific Biosciences presented at the Morgan Stanley 24th Annual Global Healthcare Conference.
Questions About the Q3 Results
The company released its third-quarter figures on November 4, 2026.
An insider sold $2,056,921 worth of shares on October 8, per an SEC filing.
Pacific Biosciences targets up to $40 million in annual savings by 2027.
The November 4 report follows the company’s August 5 second-quarter earnings call and its announcements of full-year 2026 guidance and a Vega system update.
Related reading